checkAd
    Startseite > Aktien > Sana Biotechnology > Nachrichten
    Sana Biotechnology Aktie
    6,9800
     
    USD
    -5,16 %
    -0,3800 USD
    Letzter Kurs 08.06.24 Nasdaq
    6,9800
     
    USD
    8.700 STK
    Geldkurs 07.06.24
    6,9900
     
    USD
    500 STK
    Briefkurs 07.06.24
    ISIN: US7995661045 · WKN: A2QNUE · SYM: SANA · USA

    Neueste Nachrichten

    Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other Glial
    21.05.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
    08.05.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology to Present at May and June 2024 Investor Conferences
    06.05.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
    29.02.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
    28.02.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
    13.02.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    12.02.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology Announces Pricing of Upsized Public Offering
    08.02.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology Announces Proposed Public Offering of Common Stock
    07.02.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
    05.01.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    03.01.24 · globenewswire · Sana Biotechnology
    Sana Biotechnology to Present at November and December 2023 Investor Conferences
    21.11.23 · globenewswire · Sana Biotechnology